Singapore legislation

Regulation 6

of Health Products (Clinical Research Materials) Regulations 2016

Regulation 6

Approval for export of consignments of certain clinical research materials

Amended byS 108/2021 wef 01/03/2021S 452/2022 wef 01/07/2022S 730/2021 wef 01/10/2021

Subregulation 1

Amended byS 108/2021 wef 01/03/2021

This regulation applies to any clinical research material that is a therapeutic product and that —

(a)

contains any psychotropic substance; or

(b)

is a codeine cough preparation.

Subregulation 2

Despite regulation 3(3), the person must not export the clinical research material except under and in accordance with a prior approval of the Authority for each consignment of the material to be exported.

Subregulation 3

Amended byS 452/2022 wef 01/07/2022

An application for an approval under paragraph (2) must —

(a)

be made in the form and manner specified on the Authority’s website;

(b)

be accompanied by such particulars, information, documents and samples as the Authority may require; and

(c)

be accompanied by the relevant fee, if the material contains any psychotropic substance.

Subregulation 4

Upon receiving an application under this regulation, the Authority may approve the application or refuse to approve the application.

Subregulation 5

The Authority may subject its approval to such conditions as the Authority thinks necessary and may, from time to time, by notice in writing to the person granted the approval —

(a)

modify or remove any condition of the approval; or

(b)

impose any new condition on the approval.

Subregulation 6

The Authority may, at any time, suspend or revoke any approval.

Subregulation 7

Amended byS 730/2021 wef 01/10/2021

In this regulation, “codeine cough preparation” means a therapeutic product that —

(a)

is in liquid or solid form;

(b)

contains codeine or its salts; and

(c)

is intended for the treatment of coughs.